Candriam S.C.A. Takes Position in Encompass Health Corporation $EHC

Candriam S.C.A. acquired a new position in shares of Encompass Health Corporation (NYSE:EHC) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 69,375 shares of the company’s stock, valued at approximately $6,711,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. WPG Advisers LLC lifted its holdings in Encompass Health by 73.3% in the fourth quarter. WPG Advisers LLC now owns 324 shares of the company’s stock worth $34,000 after acquiring an additional 137 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new stake in shares of Encompass Health during the 4th quarter worth approximately $37,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Encompass Health by 36,200.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company’s stock worth $46,000 after purchasing an additional 362 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of Encompass Health in the 4th quarter worth approximately $55,000. Finally, Covestor Ltd boosted its position in Encompass Health by 24.4% during the 4th quarter. Covestor Ltd now owns 540 shares of the company’s stock valued at $57,000 after purchasing an additional 106 shares during the period. Institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Down 0.1%

Shares of Encompass Health stock opened at $110.05 on Tuesday. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.76. The firm has a market cap of $10.92 billion, a price-to-earnings ratio of 18.37, a price-to-earnings-growth ratio of 2.40 and a beta of 0.74. The business has a fifty day simple moving average of $104.08 and a 200-day simple moving average of $103.50. Encompass Health Corporation has a fifty-two week low of $92.77 and a fifty-two week high of $127.99.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Thursday, April 30th. The company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.09. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. The firm’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.37 earnings per share. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. On average, equities analysts forecast that Encompass Health Corporation will post 5.97 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Wednesday, July 1st will be given a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, July 1st. Encompass Health’s dividend payout ratio (DPR) is 12.69%.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, EVP Patrick William Tuer sold 682 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $104.56, for a total transaction of $71,309.92. Following the completion of the sale, the executive vice president directly owned 24,755 shares in the company, valued at approximately $2,588,382.80. This trade represents a 2.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on EHC. Weiss Ratings cut Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, June 26th. Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Barclays reduced their target price on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research note on Tuesday, May 5th. Leerink Partners set a $152.00 price target on shares of Encompass Health in a research note on Friday, May 22nd. Finally, TD Cowen began coverage on Encompass Health in a report on Thursday, May 28th. They set a “buy” rating and a $125.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $143.86.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.